Thursday, January 05, 2023 3:51:07 PM
I fully expect that. The emergency factor has long gone out the window on this. We can trace back all the clues to:
- Effective at ~insert several COVID symptoms~ CHECK
- Tested for safety CHECK
- Available for mass/easy reproduction CHECK
- (supposed) Emergency need because of mass infection CHECK
Yet, we have continued to see reason after excu...er...reason to push this out a little further.
Look at the idea that they're even trying to raise additional funding (maybe to complete the 1000 trial patients, or other) offering at .15. Yet, just a day or two before that is announced and the SP is at .17/.18, suddenly it nose dives down to .10.
Several of us have continued to speculate that someone/something is pinning this down. There was even speculation that a "deal" was potentially on the table a few months ago, IF RVVTF would receive approval. What happened to that?!?
The blocks and the clues are lining up. *Whoever* now has roughly 60 days to jump in and either undercut this solution with their own, or try to undercut Revive and buy out the IP dirt cheap.
But we're hanging on. In fact I just dropped a few stacks more on this today, likely to take my cart back in tomorrow.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM